Cormorant Asset Management, LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $1.9 Million - $2.59 Million	-284,988 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.23 $899,393 - $1.06 Million	-115,012 Reduced 28.75%	284,988 $2.43 Million
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $395,089 - $608,477	-49,510 Reduced 11.01%	400,000 $4.92 Million
Q3 2020 Nov 16, 2020	SELL	$7.96 - $12.42 $1.99 Million - $3.11 Million	-250,490 Reduced 35.78%	449,510 $3.66 Million
Q2 2020 Aug 14, 2020	SELL	$5.4 - $13.37 $621,685 - $1.54 Million	-115,127 Reduced 14.12%	700,000 $6.72 Million
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $89,720 - $268,613	-18,273 Reduced 2.19%	815,127 $5.54 Million
Q4 2019 Feb 14, 2020	SELL	$9.77 - $15.66 $1.61 Million - $2.58 Million	-164,492 Reduced 16.48%	833,400 $12.4 Million
Q3 2019 Nov 14, 2019	SELL	$9.59 - $12.0 $1.46 Million - $1.83 Million	-152,108 Reduced 13.23%	997,892 $10.2 Million
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $11 Million - $17.2 Million	1,150,000 New	1,150,000 $12.2 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.